Market Overview

UPDATE: Morgan Stanley Reiterates On Theravance Following Anoro Launch


In a report published Thursday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Theravance (NASDAQ: THRX), but removed the $12.00 price target.

In the report, Morgan Stanley noted, “Anoro (Umec/VI) recently launched in the US. In light of the slow Breo launch, Street optimism is migrating to Anoro. Differences in starting royalty rate (15% for Breo sales <$3bn vs. 6.5% for Anoro) is one dominant reason we see it as unlikely that Anoro will ever accommodate for the likely Breo shortfall. Below, we discuss our rationale as to why we expect Anoro will launch and ramp below consensus.”

Theravance closed on Wednesday at $28.86.

Latest Ratings for THRX

May 2015Cowen & Co.DowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014StifelDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings


Related Articles (THRX)

View Comments and Join the Discussion!

Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings

Latest Ratings

PCTYJMP SecuritiesMaintains220.0
KMBRBC CapitalMaintains147.0
AZEKRBC CapitalMaintains50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at